KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Finished Goods (2018 - 2025)

Historic Finished Goods for Ionis Pharmaceuticals (IONS) over the last 8 years, with Q1 2025 value amounting to $2.1 million.

  • Ionis Pharmaceuticals' Finished Goods rose 95900.0% to $2.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.1 million, marking a year-over-year increase of 95900.0%. This contributed to the annual value of $276000.0 for FY2024, which is 7922.08% up from last year.
  • As of Q1 2025, Ionis Pharmaceuticals' Finished Goods stood at $2.1 million, which was up 95900.0% from $276000.0 recorded in Q4 2024.
  • In the past 5 years, Ionis Pharmaceuticals' Finished Goods ranged from a high of $2.1 million in Q1 2025 and a low of $63000.0 during Q3 2024
  • In the last 5 years, Ionis Pharmaceuticals' Finished Goods had a median value of $288000.0 in 2022 and averaged $563294.1.
  • In the last 5 years, Ionis Pharmaceuticals' Finished Goods tumbled by 8702.16% in 2021 and then soared by 95900.0% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Finished Goods (Quarter) stood at $390000.0 in 2021, then plummeted by 57.95% to $164000.0 in 2022, then dropped by 6.1% to $154000.0 in 2023, then skyrocketed by 79.22% to $276000.0 in 2024, then soared by 667.39% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q1 2025, $276000.0 for Q4 2024, and $63000.0 during Q3 2024.